278 related articles for article (PubMed ID: 29389671)
1. A controlled human malaria infection model enabling evaluation of transmission-blocking interventions.
Collins KA; Wang CY; Adams M; Mitchell H; Rampton M; Elliott S; Reuling IJ; Bousema T; Sauerwein R; Chalon S; Möhrle JJ; McCarthy JS
J Clin Invest; 2018 Apr; 128(4):1551-1562. PubMed ID: 29389671
[TBL] [Abstract][Full Text] [Related]
2. A randomized feasibility trial comparing four antimalarial drug regimens to induce
Reuling IJ; van de Schans LA; Coffeng LE; Lanke K; Meerstein-Kessel L; Graumans W; van Gemert GJ; Teelen K; Siebelink-Stoter R; van de Vegte-Bolmer M; de Mast Q; van der Ven AJ; Ivinson K; Hermsen CC; de Vlas S; Bradley J; Collins KA; Ockenhouse CF; McCarthy J; Sauerwein RW; Bousema T
Elife; 2018 Feb; 7():. PubMed ID: 29482720
[TBL] [Abstract][Full Text] [Related]
3. Primaquine for reducing Plasmodium falciparum transmission.
Graves PM; Gelband H; Garner P
Cochrane Database Syst Rev; 2012 Sep; (9):CD008152. PubMed ID: 22972117
[TBL] [Abstract][Full Text] [Related]
4. A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers.
McCarthy JS; Rückle T; Elliott SL; Ballard E; Collins KA; Marquart L; Griffin P; Chalon S; Möhrle JJ
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685476
[TBL] [Abstract][Full Text] [Related]
5. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open-label randomized trial.
Lin JT; Lon C; Spring MD; Sok S; Chann S; Ittiverakul M; Kuntawunginn W; My M; Thay K; Rahman R; Balasubramanian S; Char M; Lanteri CA; Gosi P; Ubalee R; Meshnick SR; Saunders DL
PLoS One; 2017; 12(6):e0168702. PubMed ID: 28591198
[TBL] [Abstract][Full Text] [Related]
6. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.
Phyo AP; Jittamala P; Nosten FH; Pukrittayakamee S; Imwong M; White NJ; Duparc S; Macintyre F; Baker M; Möhrle JJ
Lancet Infect Dis; 2016 Jan; 16(1):61-69. PubMed ID: 26448141
[TBL] [Abstract][Full Text] [Related]
7. Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai-Myanmar border populations.
Lawpoolsri S; Klein EY; Singhasivanon P; Yimsamran S; Thanyavanich N; Maneeboonyang W; Hungerford LL; Maguire JH; Smith DL
Malar J; 2009 Jul; 8():159. PubMed ID: 19604346
[TBL] [Abstract][Full Text] [Related]
8. The Gametocytocidal Efficacy of Different Single Doses of Primaquine with Dihydroartemisinin-piperaquine in Asymptomatic Parasite Carriers in The Gambia: A Randomized Controlled Trial.
Okebe J; Bousema T; Affara M; Di Tanna GL; Dabira E; Gaye A; Sanya-Isijola F; Badji H; Correa S; Nwakanma D; Van Geertruyden JP; Drakeley C; D'Alessandro U
EBioMedicine; 2016 Nov; 13():348-355. PubMed ID: 27825738
[TBL] [Abstract][Full Text] [Related]
9. Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage Plasmodium vivax Infection.
Collins KA; Abd-Rahman AN; Marquart L; Ballard E; Gobeau N; Griffin P; Chalon S; Möhrle JJ; McCarthy JS
J Infect Dis; 2022 Mar; 225(6):1062-1069. PubMed ID: 32479608
[TBL] [Abstract][Full Text] [Related]
10. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial.
Dicko A; Brown JM; Diawara H; Baber I; Mahamar A; Soumare HM; Sanogo K; Koita F; Keita S; Traore SF; Chen I; Poirot E; Hwang J; McCulloch C; Lanke K; Pett H; Niemi M; Nosten F; Bousema T; Gosling R
Lancet Infect Dis; 2016 Jun; 16(6):674-684. PubMed ID: 26906747
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Clinical Trial to Compare Plasmodium falciparum Gametocytemia and Infectivity After Blood-Stage or Mosquito Bite-Induced Controlled Malaria Infection.
Alkema M; Reuling IJ; de Jong GM; Lanke K; Coffeng LE; van Gemert GJ; van de Vegte-Bolmer M; de Mast Q; van Crevel R; Ivinson K; Ockenhouse CF; McCarthy JS; Sauerwein R; Collins KA; Bousema T
J Infect Dis; 2021 Oct; 224(7):1257-1265. PubMed ID: 32239171
[TBL] [Abstract][Full Text] [Related]
12. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection.
Sulyok M; Rückle T; Roth A; Mürbeth RE; Chalon S; Kerr N; Samec SS; Gobeau N; Calle CL; Ibáñez J; Sulyok Z; Held J; Gebru T; Granados P; Brückner S; Nguetse C; Mengue J; Lalremruata A; Sim BKL; Hoffman SL; Möhrle JJ; Kremsner PG; Mordmüller B
Lancet Infect Dis; 2017 Jun; 17(6):636-644. PubMed ID: 28363637
[TBL] [Abstract][Full Text] [Related]
13. Strategic use of antimalarial drugs that block falciparum malaria parasite transmission to mosquitoes to achieve local malaria elimination.
Abdul-Ghani R; Beier JC
Parasitol Res; 2014 Oct; 113(10):3535-46. PubMed ID: 25185662
[TBL] [Abstract][Full Text] [Related]
14. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial.
Okebe J; Bousema T; Affara M; DiTanna G; Eziefula AC; Jawara M; Nwakanma D; Amambua-Ngwa A; Van Geertruyden JP; Drakeley C; D'Alessandro U
Trials; 2015 Mar; 16():70. PubMed ID: 25887344
[TBL] [Abstract][Full Text] [Related]
15. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South sumatra, Western indonesia: an open-label, randomized, controlled trial.
Sutanto I; Suprijanto S; Kosasih A; Dahlan MS; Syafruddin D; Kusriastuti R; Hawley WA; Lobo NF; Ter Kuile FO
Clin Infect Dis; 2013 Mar; 56(5):685-93. PubMed ID: 23175563
[TBL] [Abstract][Full Text] [Related]
16. DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with
Collins KA; Rückle T; Elliott S; Marquart L; Ballard E; Chalon S; Griffin P; Möhrle JJ; McCarthy JS
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30858218
[TBL] [Abstract][Full Text] [Related]
17. Long term primaquine administration to reduce Plasmodium falciparum gametocyte transmission in hypoendemic areas.
Wilairatana P; Tangpukdee N; Krudsood S
Southeast Asian J Trop Med Public Health; 2010 Nov; 41(6):1306-11. PubMed ID: 21329302
[TBL] [Abstract][Full Text] [Related]
18. Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination.
Gerardin J; Eckhoff P; Wenger EA
BMC Infect Dis; 2015 Mar; 15():144. PubMed ID: 25887935
[TBL] [Abstract][Full Text] [Related]
19. Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether-lumefantrine.
Shekalaghe S; Mosha D; Hamad A; Mbaga TA; Mihayo M; Bousema T; Drakeley C; Abdulla S
Malar J; 2020 Jan; 19(1):34. PubMed ID: 31964380
[TBL] [Abstract][Full Text] [Related]
20. Appropriate time for primaquine treatment to reduce Plasmodium falciparum transmission in hypoendemic areas.
Wilairatana P; Krudsood S; Tangpukdee N
Korean J Parasitol; 2010 Jun; 48(2):179-82. PubMed ID: 20585538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
